Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 ...

Researchers have identified a mechanism by which acetylcholine, a neurotransmitter best known for its role in muscle control ...

The EMERGENT-3 trial, published in the Journal of the American Medical Association Psychiatry, represents a significant advancement in the treatment of schizophrenia, particularly for individuals ...

The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia ...

Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...

2 Department of Psychiatry, University of Toronto, Faculty of Medicine, 33 Russell Street, T-109 Toronto, ON M5S 2S1, Canada 3 Multimodal Imaging Group, Centre for Addiction & Mental Health, Toronto, ...

Suven Life Sciences Ltd. has received IND approval from the FDA allowing it to initiate a first-in-human phase I study of SUVN-I6107, a muscarinic M1 receptor positive allosteric modulator (PAM) as a ...

Myopia, a leading cause of visual impairment globally, can progress to serious complications like retinal and choroidal degeneration. While atropine is commonly used to manage childhood myopia, its ...